Siegfried Holding AG Share Price

Equities

SFZN

CH0014284498

Pharmaceuticals

Real-time Estimate Cboe Europe 02:11:30 19/04/2024 pm IST 5-day change 1st Jan Change
871 CHF -0.68% Intraday chart for Siegfried Holding AG -1.47% +1.69%

Financials

Sales 2024 * 1.3B 1.43B 120B Sales 2025 * 1.42B 1.57B 131B Capitalization 3.76B 4.14B 346B
Net income 2024 * 148M 163M 13.6B Net income 2025 * 172M 189M 15.81B EV / Sales 2024 * 3.16 x
Net Debt 2024 * 351M 386M 32.24B Net Debt 2025 * 313M 345M 28.81B EV / Sales 2025 * 2.87 x
P/E ratio 2024 *
25.3 x
P/E ratio 2025 *
21.8 x
Employees 3,945
Yield 2024 *
0.44%
Yield 2025 *
0.46%
Free-Float 87.68%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.86%
1 week-1.47%
Current month-5.10%
1 month-4.69%
3 months+2.64%
6 months+25.66%
Current year+1.69%
More quotes
1 week
853.00
Extreme 853
899.00
1 month
851.00
Extreme 851
934.00
Current year
827.00
Extreme 827
950.00
1 year
655.00
Extreme 655
950.00
3 years
566.00
Extreme 566
950.00
5 years
313.50
Extreme 313.5
950.00
10 years
136.20
Extreme 136.2
950.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 52 01/10/01
Director of Finance/CFO 53 01/17/01
Chief Tech/Sci/R&D Officer 56 01/19/01
Members of the board TitleAgeSince
Director/Board Member 55 01/16/01
Director/Board Member 63 01/14/01
Chairman 61 01/10/01
More insiders
Date Price Change Volume
19/24/19 874 -0.34% 408
18/24/18 877 -0.11% 5,994
17/24/17 878 -0.90% 3,479
16/24/16 886 -0.45% 4,835
15/24/15 890 +0.34% 3,262

Delayed Quote Swiss Exchange, April 19, 2024 at 01:49 pm IST

More quotes
Siegfried Holding AG is a Switzerland-based life sciences company which is active in primary and secondary drug manufacturing. The Company produces both drug substances and drug products. The drug substance portfolio includes contract development and manufacturing of both active pharmaceutical ingredients (APIs) and intermediates. The drug products portfolio comprises licensing and contract or co-development and manufacturing of oral solids and sterile. The Company's products and substances are developed for treatment of hypertension, benign prostate hyperplasia, depression, chronic myeloid leukemia, glaucoma, asthma, schizophrenia and bipolar disorders and diabetes. The Company operates production facilities in Switzerland, Germany, France, Malta, the United States, China, and Spain.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
877 CHF
Average target price
1,016 CHF
Spread / Average Target
+15.84%
Consensus